The U.S. Food and Drug Administration (FDA) has granted approval for Foundayo, a new oral GLP-1 medication developed by Eli Lilly, offering a fresh avenue for managing obesity and weight-related health issues. This significant step follows the earlier approval of Novo Nordisk’s Wegovy pill in December 2025, marking Foundayo as the second oral GLP-1 treatment available in the United States. The approval was announced on Wednesday, highlighting a rapid review process that took just 50 days from the initial submission.
A New Approach to Weight Management
Eli Lilly has positioned Foundayo as a solution for adults grappling with obesity or those with excess weight coupled with weight-related medical complications. The company emphasises that the medication is intended to be used alongside a calorie-reduced diet and heightened physical activity to maximise its effectiveness.
The FDA’s swift approval reflects an increasingly proactive approach to drug evaluation, with Commissioner Martin Makary noting, “This approval demonstrates what the FDA can achieve when we eliminate delays and prioritise fast and thorough work from the agency and industry partners.” Such rapid approvals could signal a shift in how the FDA approaches obesity treatments, a growing concern in public health.
Clinical Trial Results
During clinical trials, participants on the highest dose of Foundayo experienced an average weight loss of 27.3 pounds (12.3 kilograms), a stark contrast to the mere 2.2 pounds (0.9 kilograms) lost by those receiving a placebo. This data underscores the drug’s potential effectiveness for individuals facing challenges in managing their weight through traditional methods.
The medication will begin at a dosage of 0.8 milligrams, with increments to 2.5 mg and 5.5 mg over the course of the first two months. Further adjustments may be made based on individual responses, with a maximum dosage reaching up to 17.2 mg.
Cost Considerations and Side Effects
For those without insurance, the monthly cost of Foundayo will be approximately $149, according to Eli Lilly. While the potential benefits are significant, it is crucial to consider the side effects. Common adverse reactions reported include nausea, constipation, diarrhoea, and abdominal discomfort, alongside more serious concerns such as potential thyroid tumours, including thyroid cancer.
A recent study from the University of British Columbia raised alarms about GLP-1 medications, linking them to severe conditions like stomach paralysis and pancreatitis. Additionally, research from Harvard in 2024 indicated a correlation between these drugs and serious vision impairments, including sudden and irreversible blindness.
Regulatory Context and Future Implications
The introduction of Foundayo into the market is a notable moment in the evolving landscape of obesity treatment. With rising obesity rates globally, the approval of new medications reflects a critical need for effective interventions. The FDA’s commitment to expedited reviews may encourage further innovation within the pharmaceutical industry, potentially leading to more options for patients in the future.
Why it Matters
The approval of Foundayo is more than just another weight-loss drug; it signifies a pivotal moment in addressing obesity as a significant public health challenge. As healthcare systems grapple with the long-term effects of rising obesity rates on overall health, innovative treatments like Foundayo may offer new hope. However, it is essential to approach these developments with caution, ensuring that safety is prioritised alongside efficacy. The balance of effective weight management strategies and the potential risks of new medications will be critical to ensuring that patients receive comprehensive care in their journey towards better health.
